Zenas BioPharma (ZBIO) to Release Quarterly Earnings on Thursday

Key Points

• Q1 2026 results will be released before the market opens Thursday, May 14, with analysts forecasting (−$1.37) EPS and $25.0 million in revenue; the company’s conference call is scheduled for May 15 at 12:30 PM ET.
• The stock trades with a market cap of $1.20 billion, a negative PE of −2.67 and a 52‑week range of $8.51–$44.60, while analysts’ consensus rating is Hold with a $44.14 target (six Buys, one Hold, two Sells).
• Company insiders bought a total of 259,613 shares (~$5.22 million) in the past three months — including sizable purchases by directors Patricia L. Allen and Hongbo Lu — and insiders now own about 22% of the stock.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect the company to announce earnings of ($1.37) per share and revenue of $25.00 million for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 12:30 PM ET.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings results on Monday, April 13th. The company reported ($1.10) EPS for the quarter. On average, analysts expect Zenas BioPharma to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Zenas BioPharma Stock Up 0.3%

Shares of NASDAQ:ZBIO opened at $20.83 on Thursday. The firm has a market capitalization of $1.20 billion, a PE ratio of -2.67 and a beta of -0.61. The firm has a fifty day moving average of $22.12 and a 200 day moving average of $27.03. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. Zenas BioPharma has a 52-week low of $8.51 and a 52-week high of $44.60.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on ZBIO. Morgan Stanley increased their price target on shares of Zenas BioPharma from $19.00 to $21.00 and gave the company an "equal weight" rating in a research report on Tuesday, March 17th. Citigroup lowered their price target on Zenas BioPharma from $43.00 to $41.00 and set a "buy" rating for the company in a research report on Tuesday, March 17th. HC Wainwright reiterated a "buy" rating and issued a $44.00 price objective on shares of Zenas BioPharma in a research report on Tuesday, March 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Finally, Guggenheim raised their price target on Zenas BioPharma from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday, March 16th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $44.14.

Insider Buying and Selling

In related news, Director Patricia L. Allen bought 15,700 shares of the business's stock in a transaction dated Thursday, February 12th. The shares were purchased at an average cost of $24.85 per share, with a total value of $390,145.00. Following the completion of the purchase, the director owned 15,700 shares in the company, valued at approximately $390,145. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Hongbo Lu purchased 25,985 shares of the stock in a transaction dated Wednesday, February 11th. The stock was bought at an average cost of $22.50 per share, with a total value of $584,662.50. Following the transaction, the director owned 347,968 shares in the company, valued at $7,829,280. The trade was a 8.07% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 259,613 shares of company stock worth $5,221,863 over the last three months. 22.00% of the stock is owned by corporate insiders.

Institutional Trading of Zenas BioPharma

A number of hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Zenas BioPharma by 4.6% during the second quarter. Geode Capital Management LLC now owns 373,617 shares of the company's stock valued at $3,621,000 after buying an additional 16,461 shares during the period. Rhumbline Advisers raised its stake in Zenas BioPharma by 71.3% during the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company's stock worth $191,000 after acquiring an additional 8,207 shares during the period. Sei Investments Co. purchased a new position in Zenas BioPharma during the second quarter valued at approximately $118,000. Bank of America Corp DE boosted its position in shares of Zenas BioPharma by 32.3% in the second quarter. Bank of America Corp DE now owns 13,991 shares of the company's stock worth $136,000 after purchasing an additional 3,412 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Zenas BioPharma by 17.2% in the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company's stock worth $25,813,000 after purchasing an additional 170,546 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.